S
45.20
1.69 (3.88%)
| Penutupan Terdahulu | 43.51 |
| Buka | 43.01 |
| Jumlah Dagangan | 1,324,309 |
| Purata Dagangan (3B) | 2,632,814 |
| Modal Pasaran | 4,610,737,152 |
| Harga / Jualan (P/S) | 13.14 |
| Harga / Buku (P/B) | 18.12 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| EPS Cair (TTM) | -2.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.22% |
| Nisbah Semasa (MRQ) | 10.25 |
| Aliran Tunai Operasi (OCF TTM) | -229.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -134.32 M |
| Pulangan Atas Aset (ROA TTM) | -50.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Scholar Rock Holding Corporatio | Bercampur | Menaik |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.25 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.35% |
| % Dimiliki oleh Institusi | 118.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 53.00 (B of A Securities, 17.26%) | Beli |
| Median | 45.00 (-0.44%) | |
| Rendah | 42.00 (Wolfe Research, -7.08%) | Beli |
| Purata | 46.57 (3.03%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 36.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 18 Nov 2025 | 47.00 (3.98%) | Beli | 39.81 |
| Wolfe Research | 18 Nov 2025 | 42.00 (-7.08%) | Beli | 39.81 |
| Barclays | 17 Nov 2025 | 45.00 (-0.44%) | Beli | 36.47 |
| 24 Sep 2025 | 44.00 (-2.65%) | Beli | 33.72 | |
| Truist Securities | 20 Oct 2025 | 44.00 (-2.65%) | Beli | 27.92 |
| B of A Securities | 09 Oct 2025 | 53.00 (17.26%) | Beli | 40.99 |
| Piper Sandler | 24 Sep 2025 | 51.00 (12.83%) | Beli | 33.72 |
| HC Wainwright & Co. | 23 Sep 2025 | 44.00 (-2.65%) | Beli | 33.75 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | Scholar Rock to Present at Upcoming Investor Conferences |
| 14 Nov 2025 | Pengumuman | Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Pengumuman | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference |
| 23 Oct 2025 | Pengumuman | Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 |
| 17 Oct 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Sep 2025 | Pengumuman | FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility |
| 12 Sep 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |